BIOSPECIFICS TECHNOLOGIES CORP - FORM 10-K - EX-23.1 - EXHIBIT 23.1 - March 16, 2020

Attached files

file filename
EX-32.1 - EXHIBIT 32.1 - BIOSPECIFICS TECHNOLOGIES CORPex32_1.htm
EX-31.2 - EXHIBIT 31.2 - BIOSPECIFICS TECHNOLOGIES CORPex31_2.htm
EX-31.1 - EXHIBIT 31.1 - BIOSPECIFICS TECHNOLOGIES CORPex31_1.htm
EX-21.1 - EXHIBIT 21.1 - BIOSPECIFICS TECHNOLOGIES CORPex21_1.htm
EX-10.31 - EXHIBIT 10.31 - BIOSPECIFICS TECHNOLOGIES CORPex10_31.htm
EX-10.30 - EXHIBIT 10.30 - BIOSPECIFICS TECHNOLOGIES CORPex10_30.htm
EX-10.5 - EXHIBIT 10.5 - BIOSPECIFICS TECHNOLOGIES CORPex10_5.htm
EX-4.7 - EXHIBIT 4.7 - BIOSPECIFICS TECHNOLOGIES CORPex4_7.htm
10-K - 10-K - BIOSPECIFICS TECHNOLOGIES CORPform10k.htm
Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statement of BioSpecifics Technologies Corp. on Forms S-8 (Nos. 333-232351 and 333-160583) of our reports dated March 16, 2020, on our audits of the consolidated financial statements as of December 31, 2019 and 2018 and for each of the years ended and the effectiveness of BioSpecifics Technologies Corp.’s internal control over financial reporting as of December 31, 2019, which reports are included in this Annual Report on Form 10-K to be filed on or about March 16, 2020.

/s/ EisnerAmper LLP

EISNERAMPER LLP
New York, New York
March 16, 2020


Stock widget

Investing forum

BIOSPECIFICS TECHNOLOGIES CORP Reports